A detailed history of Venturi Wealth Management, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Venturi Wealth Management, LLC holds 2,845 shares of BGNE stock, worth $421,003. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,845
Previous 1,521 87.05%
Holding current value
$421,003
Previous $274,000 62.04%
% of portfolio
0.03%
Previous 0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$141.8 - $181.47 $187,743 - $240,266
1,324 Added 87.05%
2,845 $444,000
Q4 2023

Jan 23, 2024

SELL
$158.67 - $201.58 $6,664 - $8,466
-42 Reduced 2.69%
1,521 $274,000
Q3 2023

Nov 02, 2023

SELL
$179.87 - $225.13 $84,538 - $105,811
-470 Reduced 23.12%
1,563 $281,000
Q1 2023

May 02, 2023

BUY
$215.53 - $274.5 $33,407 - $42,547
155 Added 8.25%
2,033 $438,000
Q4 2022

Jan 31, 2023

SELL
$125.51 - $229.3 $2,635 - $4,815
-21 Reduced 1.11%
1,878 $413,000
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $250,288 - $384,053
1,899 New
1,899 $256,000
Q2 2022

Aug 12, 2022

SELL
$121.11 - $216.05 $232,288 - $414,383
-1,918 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$146.52 - $269.56 $16,556 - $30,460
113 Added 6.26%
1,918 $362,000
Q4 2021

Feb 08, 2022

BUY
$248.56 - $389.34 $24,856 - $38,934
100 Added 5.87%
1,805 $489,000
Q3 2021

Oct 19, 2021

BUY
$249.6 - $403.14 $18,969 - $30,638
76 Added 4.67%
1,705 $619,000
Q2 2021

Aug 02, 2021

BUY
$292.75 - $367.01 $26,640 - $33,397
91 Added 5.92%
1,629 $559,000
Q1 2021

Apr 22, 2021

BUY
$260.64 - $382.12 $107,644 - $157,815
413 Added 36.71%
1,538 $535,000
Q4 2020

Jan 28, 2021

BUY
$221.31 - $316.61 $43,819 - $62,688
198 Added 21.36%
1,125 $291,000
Q3 2020

Nov 03, 2020

BUY
$189.18 - $286.44 $168,559 - $255,218
891 Added 2475.0%
927 $266,000
Q3 2019

Oct 29, 2019

BUY
$120.61 - $148.29 $4,341 - $5,338
36 New
36 $4,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $15.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Venturi Wealth Management, LLC Portfolio

Follow Venturi Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Venturi Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Venturi Wealth Management, LLC with notifications on news.